Neurocrine reports Q4 adjusted EPS $1.69, consensus $1.93
Reports Q4 revenue $627.7M, consensus $629.44M. “I’m proud of the tremendous progress we made last year with the continued growth of INGREZZA ...
American Association of Individual Investors7h
Which Is a Better Investment, Biogen Inc. or Neurocrine Biosciences, Inc. Stock?
Learn more about whether Biogen Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
Investor's Business Daily on MSN5h
Neurocrine Crumbles On Lackluster Guidance For Its Bread-And-Butter Drug
Neurocrine stock took a hit late Thursday after the biotech company issued a light 2025 outlook for its drug, Ingrezza.
Neurocrine sees FY25 Ingrezza net product sales $2.5B-$2.6B
FY25 revenue consensus $2.79B.Maximize Your Portfolio with Data Driven Insights:Leverage the power of TipRanks' Smart Score, a data-driven tool ...
Neurocrine Biosciences officer sells $168,849 in stock
David W. Boyer, the Chief Corporate Affairs Officer at Neurocrine Biosciences Inc. (NASDAQ:NBIX), a biopharmaceutical company ...
Earnings Summary: Neurocrine Biosciences Q4
Neurocrine Biosciences missed estimated earnings by -1.0%, reporting an EPS of $1.69 versus an estimate of $1.71. Revenue was up $112.50 million from the same period last year. During the previous ...
FierceBiotech9d
Takeda regains home rights to phase 3-stage depression drug from Neurocrine
Takeda is taking back the home license for a phase 3-stage depression drug as part of an amendment to its multi-asset ...
Neurocrine price target raised to $184 from $182 at BofA
BofA raised the firm’s price target on Neurocrine (NBIX) to $184 from $182 and keeps a Buy rating on the shares. The firm, which highlights ...